Dr. Saab on Immunotherapy in MSI-H GI Malignancies

Tanios Bekaii-Saab, MD
Published: Friday, Sep 22, 2017



Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

Patients whose disease lacks the expression of some proteins would be classified as MSI-H, which is found in 4% of patients. This is a surrogate marker for tumors that are loaded with mutations, states Bekaii-Saab.

The presence of MSI-H phenotype is dependent on 2 elements. Firstly, it could be acquired through the genetics of the patient. Secondly, patients could acquire this sporadically, which is the majority of patients in the metastatic setting.
 


Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

Patients whose disease lacks the expression of some proteins would be classified as MSI-H, which is found in 4% of patients. This is a surrogate marker for tumors that are loaded with mutations, states Bekaii-Saab.

The presence of MSI-H phenotype is dependent on 2 elements. Firstly, it could be acquired through the genetics of the patient. Secondly, patients could acquire this sporadically, which is the majority of patients in the metastatic setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x